Cyclosporine News and Research

RSS
Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
New system safe, effective in delivering CsA to organ transplant patients

New system safe, effective in delivering CsA to organ transplant patients

New consensus guidelines for treatment of plaque psoriasis

New consensus guidelines for treatment of plaque psoriasis

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

Treatments for lymphoma with no side effects

Treatments for lymphoma with no side effects

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Researchers examine effects of antirejection drugs in kidney transplant patients

Researchers examine effects of antirejection drugs in kidney transplant patients

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Combination drug regimen safe and effective for renal transplant patients

Combination drug regimen safe and effective for renal transplant patients

FDA approves NULOJIX

FDA approves NULOJIX

Bristol-Myers Squibb receives FDA approval for Nulojix to prevent organ rejection after kidney transplant

Bristol-Myers Squibb receives FDA approval for Nulojix to prevent organ rejection after kidney transplant

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Isotechnika reports consolidated net loss of $2.9 million for first quarter 2011

Isotechnika reports consolidated net loss of $2.9 million for first quarter 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Merck, Inspire announce expiration of HSR waiting period for cash tender offer

Merck, Inspire announce expiration of HSR waiting period for cash tender offer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.